Skip to main content

Recent articles

Takeda draws a cautious line under Iclusig

$100m buys an option over another third-gen drug, but Scemblix casts a long shadow.

EHA 2024 – Syndax sets up another menin inhibitor battle

Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

EHA 2024 – J&J bows out as Roche looks to confirm

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

EHA 2024 – In8bio bets on a registrational plan

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

We haven't lost focus, BioNTech insists

The company defends its cancer strategy, and says it's not a me-too developer.

Bayer changes tack in targeted lung cancer

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.